Glucagon-like peptide-1 mimetics improve certain cardiovascular risk factors, although it is unclear if the observed benefits are direct effects or indirect effects due to weight loss. Improvements in systolic blood pressure seen in exenatide and liraglutide trials are illustrated in Figure 3. The decreases in systolic blood pressure range from …
Read More »GLP-1 Knowledge Survey Part III
This week we examine more of your responses regarding GLP-1 therapy…. See more GLP-1 Agonist Resources. I was glad to see that almost everyone realized that when a GLP-1 agonist is added to a sulfonylurea that it is not the GLP-1 agonist that is responsible for any side effects. It’s …
Read More »GLP-1 Knowledge Survey Part II
We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered…. It appears that most of you knew that a large amount of GLP-1 production is lost …
Read More »GLP-1 Knowledge Survey Part I
Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs are…. We asked you “what were the most important things …
Read More »